Penumbra, Inc. PEN is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The stock has an Earnings ESP of +11.11% and sports a Zacks Rank of 1 at present. PEN beat earnings estimates in the last reported quarter. Penumbra has a four-quarter earnings surprise of 37.56%, on average. Penumbra’s stock has gained 51.4% in the past six months. A medical stock worth considering as it has the right combination of elements to post an earnings beat this quarter.
Axos Financial Inc. AX is the holding company for BofI Federal Bank, which provides financing for single and multifamily residential properties, small-to-medium size businesses in target sectors and selected specialty finance receivables.The company came out with quarterly earnings beating the Zacks Consensus Estimate. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Axos Financial posted revenues for the quarter ended December 2022, also surpassing the Zacks Consensus Estimate. The company has also topped consensus revenue estimates four times over the last four quarters. The estimate revisions trend for Axos Financial is currently favorable. It has outperformed the market so far this year.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners UpPenumbra, Inc. (PEN) : Free Stock Analysis Report
AXOS FINANCIAL, INC (AX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
